RT Journal Article
SR Electronic
T1 Toward adoption of health risk assessment in population-based and clinical scenarios
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.02.23292593
DO 10.1101/2023.08.02.23292593
A1 Gonzalez-Colom, Ruben
A1 Monterde, David
A1 Papa, Roberta
A1 Kull, Mart
A1 Anier, Andres
A1 Balducci, Francesco
A1 Cano, Isaac
A1 Coca, Marc
A1 De Marco, Marco
A1 Franceschini, Giulia
A1 Hinno, Saima
A1 Pompili, Marco
A1 Vela, Emili
A1 Piera-Jiménez, Jordi
A1 Pérez, Pol
A1 Roca, Josep
A1 the JADECARE consortium
YR 2023
UL http://medrxiv.org/content/early/2023/08/04/2023.08.02.23292593.abstract
AB Introduction Health risk assessment (HRA) strategies are cornerstone for health systems transformation toward value-based patient-centred care. However, steps for HRA adoption are undefined. This report analyses the process of transference of the Adjusted Morbidity Groups (AMG) algorithm from the Catalan Good Practice to the Marche region (IT) and to Viljandi Hospital (EE), within the JADECARE initiative (2020–2023).Description The implementation research approach involved a twelve-month pre-implementation period to assess feasibility and define the local action plans, followed by a sixteen-month implementation phase. During the two periods, a well-defined combination of experience-based co-design and quality improvement methodologies were applied.Discussion The evolution of the Catalan HRA strategy (2010–2023) illustrates its potential for health systems transformation, as well as its transferability. The main barriers and facilitators for HRA adoption were identified. The report proposes a set of key steps to facilitate site customized deployment of HRA contributing to define a roadmap to foster large-scale adoption across Europe.Conclusions Successful adoption of the AMG algorithm was achieved in the two sites confirming transferability. Marche identified the key requirements for a population-based HRA strategy, whereas Viljandi Hospital proved its potential for clinical use paving the way toward value-based healthcare strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by JADECARE project-HP-JA-2019 - Grant Agreement n. 951442 a European Union Health Program 2014-2020.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research exclusively employed fully anonymized retrospective health records sourced from administrative databases. Consequently, in compliance with prevailing legislation in the regions where the analyses were conducted, neither informed consent nor ethical committee approval was required. All the analytical procedures were undertaken under the auspices of the JADECARE project.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDue to the nature of the research and to ethical aspects, supporting data is not available.ACPAdvanced Chronic PatientsAMGAdjusted Morbidity GroupsCCPComplex Chronic PatientsCOPDChronic Obstructive Pulmonary DiseaseCRGClinical Risk GroupsGDPRGeneral Data Protection RegulationHADHealthcare Administrative DatabaseHRAHealth Risk AssessmentKPIKey Performance IndicatorLAPLocal Action PlanMSIQModules for Monitoring Quality Indicators (“Moduls pel Seguiment d’Indicadors de Qualitat”)NANext AdopterNCDNon-Communicable DiseaseoGPOriginal Good PracticePDSAPlan-Do-Study-ActPREMPatient Reported Experience MeasurePROMPatient Reported Outcome Measure